Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer
Innovations in ovarian cancer treatment: PARP inhibitors
Should all platinum sensitive patients recieve PARP inhibitors?
Where can PARP inhibitors be used
How can germline mutations distinguish risk for lethal and indolent prostate cancer?